FDA accepts Eisai Aricept transdermal patch NDA for review
Aricept transdermal patch NDA, if approved, is expected to be marketed by Eisai Inc, Easai’s US subsidiary, where it will co-promote the patch in collaboration with Pfizer. Easai
Amgen has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Repatha (evolocumab) supporting its broader use prior to a first heart attack or stroke.
PrimeSuite 2011 is a pre-market CCHIT Certified 2011 Ambulatory EHR, additionally certified for Child Health and Cardiovascular Medicine, with optional Advanced Reporting. VHA Purchased Services and Strategic Outsourcing
The trial was a randomised, double-blind, placebo-controlled study in 150 patients to evaluate the safety, tolerability and efficacy of daily TT-223 treatments in combination with weekly administrations of